Intersect ENT Announces Acquisition of Fiagon AG Medical Technologies

Potsdam/Hennigsdorf 17.09.2020 With the conclusion of negotiations on the evening of 14 September 2020 and the approval of the shareholders and the Supervisory Board of Fiagon, the company announces the acquisition by California-based Intersect ENT, Inc. (Nasdaq: XENT). With its innovative electromagnetic surgical navigation solutions, Fiagon has shaped the ENT market (ear, nose and throat diseases) in recent years and successfully entered the US market following product approval by the US authorities. With this acquisition, Intersect ENT expands its portfolio of solutions for the ENT market and expands its geographic reach in the distribution of complex, more comprehensive surgical solutions.

Thomas Krause, Chairman of the Supervisory Board of Fiagon AG and Managing Director of Branden-burg Kapital, explains: "Following our entry in 2011, we actively supported Fiagon in its development and consistently focused on an innovation leadership in its strategic orientation. That is now paying off. We are thrilled that Intersect has been able to win a partner with strong sales power, especially in the highly attractive US market. Together, the two companies now have the opportunity to play a decisive role in the further development of the ENT market worldwide."

Founded in 2007, Fiagon's mission is to improve patient outcomes by equipping physicians with their proprietary, easy-to-use, accurate integrated surgical navigation solutions.

"With the acquisition by Intersect, we have taken a huge step towards further establishing our product portfolio worldwide. With Brandenburg Kapital's entry with Fiagon, we had a reliable and constructive partner at our side who always worked towards Fiagon's vision and supported us in decisive phases as an investor and in an executive function as a member of the supervisory board," emphasizes Dr. Kai Desinger, President and CEO of the Fiagon Group.

Kai Desinger continues: "We are delighted to join Intersect ENT’s team, an established market leader with an advanced therapeutic platform in the large and attractive global ENT market. The combination of Intersect ENT's compelling product offering combined with its deep commercial leadership and im-pressive sales team provides us with a unique opportunity to share our core competencies, innovation and commercialization. We look forward to working with the Intersect ENT team to expand the market penetration of our instruments and tools worldwide".

About Fiagon

Fiagon develops and manufactures state-of-the-art surgical navigation devices with its proprietary tip-track technology. Over the last ten years, Fiagon, together with world-renowned physicians, has changed the standard of ENT navigation with its easy-to-use electromagnetic technology. This unique technology is currently also used in oral and maxillofacial surgery, neurosurgery and spinal surgery outside the USA, especially in Europe and Asia. Fiagon's navigation system supports both routine and complex ENT procedures, prompting surgeons to track the full range of instruments used during functional endoscopic sinus surgery (FESS).

Fiagon's proprietary instruments use tip-track technology and require no calibration, making them ex-tremely intuitive and easy to use. The instruments and the sinuplasty balloon can be bent and adjusted to accommodate different anatomical structures within the sinuses, allowing ENT surgeons to maxim-ize efficiency within their procedures.

About Brandenburg Kapital GmbH/ Investment Bank of the State of Brandenburg

The Investment Bank of the State of Brandenburg (ILB) manages various equity funds that finance growth- and innovation-oriented companies which have their headquarters and/or permanent establishments in Brandenburg. The funds for the early-stage and growth fund of Brandenburg Kapital, which was set up on behalf of the Brandenburg Ministry of Economic Affairs, are currently provided by the European Regional Development Fund and ILB's own resources. The investment activities of ILB have so far accompanied 228 companies on their growth path with around EUR 248 million. Around 9,000 modern jobs have been created or secured. The funds managed by ILB cover the entire spectrum from venture capital financing in the start-up and ear-ly growth phase to mezzanine financing for established medium-sized companies. In addition, private investors have invested more than 450 million euros in the companies so far.

For more information visit: www.brandenburg-kapital.de